SCHEMBL3385329

SCHEMBL3385329

NC(c1ccccn1)c1nc(Cl)nc2scc(-c3ccc(F)cc3)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 3/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
ESR1 P03372 5/20 0.39
KDM4E B2RXH2 3/20 0.38
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
FGFR1 P11362 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
SIRT5 Q9NXA8 1/20 0.36
DAPK3 O43293 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3387889 0.91 LMNA (0.50) LMNASMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL3386731 0.87 LMNA (0.39) LMNASMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL3387950 0.84 LMNA (0.52) LMNASMN1; SMN2ALDH1A1RAB9AKDM4E
SCHEMBL2903658 0.82 LMNA (0.43) LMNASMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL2369179 0.81 HTT (0.38) LMNASMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL3387494 0.80 HTT (0.44) LMNASMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL2897590 0.78 LMNA (0.44) LMNASMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL3383431 0.77 ALDH1A1 (0.44) LMNASMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL2368911 0.77 LMNA (0.45) LMNASMN1; SMN2ALDH1A1HPGDRAB9A
SCHEMBL3387596 0.77 LMNA (0.42) LMNASMN1; SMN2ALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 LMNA 1126/4885SMN1; SMN2 1520/4885ALDH1A1 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.